Wide Ranks

GRFS

Grifols, S.A.

8.07

Top Statistics
Market Cap 6 B Forward PE 7.55 Revenue Growth 12.20 %
Current Ratio 2.26 Trailing PE 32.28 Earnings Growth 0.00 %
Profit Margins 2.31 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 13.64 Enterprise / Revenue 2.45 Price To Sales Trailing12 Months 0.9011
Profitability
Profit Margins 2.31 % Operating Margins 20.06 %
Balance Sheet
Total Cash 806 M Total Cash Per Share 1.19 Total Debt 9 B
Total Debt To Equity 123.24 Current Ratio 2.26 Book Value Per Share 7.87
All Measures
Short Ratio 707.00 % Message Board Id finmb_734865 Fax 34 938 008 000
Shares Short Prior Month 4 M Return On Equity 0.0271 City Barcelona
Uuid ff4804c3-7e74-32e2-af9a-01ef612b3fc8 Previous Close 8.72 First Trade Date Epoch Utc 1 B
Book Value 7.87 Beta 0.6920 Total Debt 9 B
Volume 3 M Price To Book 1.03 Last Split Date 1 B
Fifty Two Week Low 5.30 Total Cash Per Share 1.19 Total Revenue 7 B
Shares Short Previous Month Date 1 B Target Median Price 11.15 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins 20.06 % Last Dividend Value 0.4560
Target Mean Price 10.76 Net Income To Common 161 M Implied Shares Outstanding 782 M
Trailing Peg Ratio 21.62 % Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M
Average Volume10days 1 M Total Cash 806 M Next Fiscal Year End 1 B
Revenue Per Share 5.15 Ebitda Margins 17.97 % Trailing PE 32.28
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 8.72
Target Low Price 8.93 Gmt Off Set Milliseconds -18000000 Fifty Day Average 8.82
Open 7.62 Free Cashflow 430 M Dividend Yield 0.00 %
Return On Assets 0.0287 Time Zone Short Name EST Trailing Eps 0.2500
Day Low 7.53 Address1 Avinguda de la Generalitat, 152 Shares Outstanding 257 M
Price Hint 2 Target High Price 11.80 Website https://www.grifols.com
52 Week Change -0.1672 Average Volume 992003 Earnings Quarterly Growth -13.20 %
Forward Eps 1.12 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 77.00 % Last Split Factor 2:1 Regular Market Day High 8.40
Is_sp_500 False Profit Margins 2.31 % Debt To Equity 123.24
Fifty Two Week High 12.15 Day High 8.40 Shares Short 3 M
Regular Market Open 7.62 Industry Key drug-manufacturers-general Earnings Growth 0.00 %
Enterprise To Revenue 2.45 Revenue Growth 12.20 % Shares Percent Shares Out 0.0055
Operating Cashflow 527 M Five Year Avg Dividend Yield 240.00 % Currency USD
Market Cap 6 B Time Zone Full Name America/New_York Is_nasdaq_100 False
Zip 08174 Quote Type EQUITY Industry Drug Manufacturers - General
Ex Dividend Date 1 B Regular Market Day Low 7.53 Held Percent Institutions 0.5630
Long Name Grifols, S.A. Current Price 8.07 Address2 Parc empresarial Can Sant Joan Sant Cugat del Valles
Enterprise To Ebitda 13.64 Financial Currency EUR Current Ratio 2.26
Gross Margins 39.18 % Industry Disp Drug Manufacturers - General Number Of Analyst Opinions 4
Country Spain Float Shares 547 M Two Hundred Day Average 7.76
Enterprise Value 17 B Price To Sales Trailing12 Months 0.9011 Forward PE 7.55
Regular Market Volume 3 M Last Dividend Date 1 B Ebitda 1 B
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Grifols, S.

A.

operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.

The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies.

In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug.

Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development.

Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG.

It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies.

The company was founded in 1909 and is headquartered in Barcelona, Spain.